Non Muscle Invasive Bladder Cancer Pipeline, Clinical Trials and Emerging Therapy Assessment by DelveInsight

February 26 02:17 2021
Non Muscle Invasive Bladder Cancer Pipeline, Clinical Trials and Emerging Therapy Assessment by DelveInsight

DelveInsight has launched a new report on Non Muscle Invasive Bladder Cancer Pipeline

 

Non-muscle invasive bladder cancer (NMIBC) formerly known as superficial bladder cancer, is a common, heterogeneous disease associated with high rates of recurrence that often requires lifelong surveillance. The cancer is found in the tissue that lines the inner surface of the bladder wherein the bladder muscle is not involved.

 

Request for free sample copy- https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight

 

Non Muscle Invasive Bladder Cancer Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of Non Muscle Invasive Bladder Cancer Pipeline products with detailed clinical profiles, key cross -competition, launch date along with product development activities.

 

Non Muscle Invasive Bladder Cancer Pipeline

The high-grade NMIBC pipeline possesses potential drugs in mid and late stage developments to be launched in the near future. The major key players include Viventia Bio/Sesen Bio (Vicinium), FKD Therapies Oy/Ferring Pharmaceuticals (Adstiladrin), CG Oncology (CG0070), ImmunityBio/Altor Biosciences (N-803 (ALT-803)), Theralase (TLD-1433), Merck (Keytruda) and others that hold the potential to create a significant positive shift in NMIBC in the market size.

 

Marketed drugs included in the report

  • Keytruda (pembrolizumab): Merck
  • Valstar (valrubicin): Endo Pharmaceuticals

 

Emerging drugs included in the report

  • Vicinium: Sesen Bio
  • Adstiladrin (nadofaragene firadenovec/Syn3): FKD Therapies Oy/ Ferring Pharmaceuticals
  • Tecentriq (atezolizumab): Hoffmann-La Roche
  • Sasanlimab (PF-06801591) + BCG: Pfizer
  • And many others

 

Non Muscle Invasive Bladder Cancer Treatment

The main treatments when the cancer cells are found only in the bladder’s inner lining (non-muscle-invasive bladder cancer) are surgery, intravesical immunotherapy (BCG) andintravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases.

The market is expected to grow by factors like the expected entry of emerging therapies with novel targets and pricing. Furthermore, the upcoming products such as Adstiladrin, Vicinium, N-803, TLD-1433, CG0070 and Keytruda are anticipated to expand the market with a deeper penetration in the 7MM.

 

Non Muscle Invasive Bladder Cancer Symptoms

  • Some people may have symptoms that suggest they have bladder cancer. Others may feel nothing at all. Some symptoms should never be ignored. Some of the common symptoms are:
  • Hematuria (blood in the urine) – the most common symptom, often without pain
  • Frequent and urgent urination
  • Pain when urine passes
  • Pain in lower abdomen
  • Back pain

 

Non Muscle Invasive Bladder Cancer Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Non-muscle invasive bladder cancer R&D. The therapies under development are focused on novel approaches to treat/improve Non-muscle invasive bladder cancer.
  • In August 2018, Sesen Bio announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Vicinium for the treatment of BCG-unresponsive high-grade non-muscle invasive bladder cancer (NMIBC).
  • The FDA granted Instiladrin, Breakthrough Therapy designation and its Biologics License Application (BLA) has been accepted for filing and granted Priority Review.
  • In September 2019, Anchiano Therapeutics reported that it had entered into an exclusive worldwide collaboration and option to license agreement with ADT Pharmaceuticals to develop novel small-molecule inhibitors of RAS and PDE10/β-catenin. This collaboration reflects Anchiano’s ongoing strategy to grow a pipeline beyond its pivotal-stage asset, inodiftagene vixteplasmid, with programs that have the potential to address significant clinical needs, while leveraging Anchiano’s expertise in small-molecule oncology development.
  • LiPax Platform is a proprietary proliposomal intracavitary paclitaxel drug delivery platform designed to enhance the therapeutic index of proven cancer drugs, which results in more effective treatments for intracavitary cancers. LIPAC’s lead drug candidate, LiPax, is a locally delivered formulation of the well-established chemotherapy drug, paclitaxel. It is in Phase 1/2a clinical trial for non-muscle invasive bladder cancer (NMIBC) and has demonstrated impressive initial clinical activity while being very well tolerated. LiPax is also in preclinical development for upper tract urothelial carcinoma (UTUC), ovarian cancer, intraperitoneal carcinoma, and mesothelioma/malignant pleural effusion.

 

Request for free sample copy- https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight

 

Table of content

 

Introduction

Executive Summary

Non-muscle invasive bladder cancer: Overview

Pipeline Therapeutics

Therapeutic Assessment

Non-muscle invasive bladder cancer – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Non-muscle invasive bladder cancer Collaboration Deals

Late Stage Products

Vicinium : Sesen Bio

APL-1202: Asieris Pharmaceuticals

Mid Stage Products

UGN-102: UroGen Pharma

Balversa: Janssen Pharmaceuticals

Early Stage Products

UGN-201: UroGen Pharma

E7766: H3 Biomedicine

Pre-clinical and Discovery Stage Products

ATX 101: APIM Therapeutics

Inactive Products

Non Muscle Invasive Bladder Cancer Key Companies

Non Muscle Invasive Bladder Cancer Key Products

Non Muscle Invasive Bladder Cancer- Unmet Needs

Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers

Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion

Non Muscle Invasive Bladder Cancer Analyst Views

Non Muscle Invasive Bladder Cancer Key Companies

Appendix

 

Related Reports

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/giridihjournal.in/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7